FLGT News and Press, Fulgent Genetics Inc. From 04/27/22

AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC. PR Newswire NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announc...

Genetic testing company Fulgent Genetics (NASDAQ: FLGT) has had a wild ride over the past few years. At the beginning of the pandemic, Fulgent experienced parabolic revenue growth when it was able to pivot from its core, next-generation sequencing (NGS) business to produce COVID...

Fulgent Genetics (NASDAQ:FLGT) to acquire Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners. Total purchase price of ~$170M, closing expected in Q2. For Q1, anticipates total revenue to be ~$300...

Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent’s rapidly expanding genomic testing footprint Preliminary first quar...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...

Fulgent Genetics reported a better-than-expected FQ4 card. But, it could get much more challenging from FY22. Nonetheless, the company authorized a significant $250M stock repurchase program in early March. We discuss why FLGT stock remains a Buy. For further details see: ...

Since 2020, many investors have developed exceptionally high expectations for the stock market because of the jaw-dropping performances of some companies. Fulgent Genetics (NASDAQ: FLGT) , for example, gave investors over 763% returns from the start of 2020 to March 2021. Other stoc...

Fulgent Genetics is experiencing significant topline growth because of the COVID-19 testing services; The company’s core business revenue also grew by almost 3 times, and the diluted EPS doubled Year-on-Year; The emergence of the Omicron variant and Fulgent’s progres...

Fulgent Genetics (NASDAQ:FLGT) is +4.31% pre-market after announcing a share repurchase program under which it may buyback $250M of its common stock. The program will be funded using Fulgent's working capital. The genetic testing company had ~30.3M shares of common stock outstanding...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that its Board of Directors...